Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Trends in antibiotic susceptibility and genetic beta-lactam resistance patterns among Haemophilus influenzae cases isolated from adult patients with respiratory tract infection].
Hagiwara E, Watanuki Y, Shiihara J, Matsushima A, Enomoto T, Sekine A, Tsuchiya N, Baba T, Shinohara T, Endo T, Sogo Y, Nishihira R, Komatsu S, Kato T, Ogura T, Takahashi H. Hagiwara E, et al. Among authors: shiihara j. Kansenshogaku Zasshi. 2009 Jul;83(4):355-62. doi: 10.11150/kansenshogakuzasshi.83.355. Kansenshogaku Zasshi. 2009. PMID: 19697870 Japanese.
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S, Kishikawa T, Shiono A, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Minato K, Kagamu H. Imai H, et al. Among authors: shiihara j. Invest New Drugs. 2022 Oct;40(5):1066-1079. doi: 10.1007/s10637-022-01269-9. Epub 2022 Jun 24. Invest New Drugs. 2022. PMID: 35749041 Free PMC article.
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: shiihara j. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H. Wasamoto S, et al. Among authors: shiihara j. Front Oncol. 2023 Jan 20;12:1080729. doi: 10.3389/fonc.2022.1080729. eCollection 2022. Front Oncol. 2023. PMID: 36741711 Free PMC article.
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M, Tambo Y, Sonoda T, Miyazaki A, Uematsu S, Tsuchiya-Kawano Y, Yanagitani N, Nishino M. Hasegawa T, et al. Among authors: shiihara j. Cancer Chemother Pharmacol. 2023 Jul;92(1):29-37. doi: 10.1007/s00280-023-04547-2. Epub 2023 May 27. Cancer Chemother Pharmacol. 2023. PMID: 37243795
27 results